potassium voltage-gated channel subfamily D member 3Genealiases: BRGDA9 · KCND3L · KCND3S · KSHIVB · KV4.3 · SCA19
Q-omics provides the consensus-scored KCND3 profile across patient tissues and cancer cell-line models. KCND3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KCND3 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, KCND3 RNA expression shows 21,151 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, KICH, and LSCC as cancer lineages where KCND3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCND3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCND3 survival associations across molecular data types. KCND3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCND3 RNA expression–survival associations across cancer types. High KCND3 expression shows unfavorable associations in BLCA and UVM, but favorable associations in BRCA, SARC, MESO and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for KCND3 RNA expression.
This table summarizes KCND3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCND3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCND3 shows lower tumor expression in KICH, KIRC, THCA, BLCA, UCEC and COAD. The KICH box plot shows higher KCND3 RNA expression in normal versus tumor tissue (log2 FC = −2.102, t-test p < 0.001).
This table shows molecular features associated with KCND3 in patient tissues and cancer cell lines. In patient samples, KCND3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCND3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
